Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
4.76% $0.300
America/New_York / 3 nov 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 10.94 mill |
EPS: | -1.900 |
P/E: | -0.158 |
Earnings Date: | Nov 01, 2023 |
SharesOutstanding: | 36.52 mill |
Avg Daily Volume: | 0.135 mill |
RATING 2023-11-03 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.158 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.03x |
Company: PE -0.158 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.249 - 0.351 ( +/- 17.02%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-27 | Meyers Rachel | Buy | 12 551 | Stock Option (Right to Buy) |
2023-11-27 | Meyers Rachel | Buy | 0 | |
2023-11-22 | Lucchino David L. | Sell | 110 | Common Stock |
2023-11-22 | Lucchino David L. | Sell | 230 | Common Stock |
2023-11-22 | Lucchino David L. | Sell | 614 | Common Stock |
INSIDER POWER |
---|
96.43 |
Last 81 transactions |
Buy: 3 077 272 | Sell: 64 406 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.300 (4.76% ) |
Volume | 0.309 mill |
Avg. Vol. | 0.135 mill |
% of Avg. Vol | 228.88 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.